FLT3 and acute myeloid leukemia: Another clinical trial, in which 27 newly diagnosed elderly (61–86 years) AML patients with FLT3-ITD mutation were treated with sorafenib plus azacitidine, resulted in 78% of overall response rate (ORR) suggesting that azacitidine and sorafenib combination is well tolerated and effective to treat older patients with FLT3-ITD-mutated AML who have not received previous treatment (NCT02196857) [235].